Figure 4.
Mutant NPM1 MRD detection in patients with AML with a concomittant FLT3-ITD. (A) Relapse incidence of mutant NPM1 (mNPM1) MRD (NGS/DNA, >0.01% VAF) in patients with AML without FLT3-ITD at diagnosis. Patients with detectable mNPM1 MRD indicated in yellow, patients without detectable NPM1 MRD indicated in purple. (B) Relapse incidence of mNPM1 MRD (NGS/DNA, >0.01% VAF) in patients with AML with a FLT3-ITD at diagnosis. Patients with detectable mNPM1 MRD indicated in yellow, patients without detectable NPM1 MRD indicated in purple. (C) Relapse incidence of patients with AML with and without mNPM1 MRD in patients with AML with a FLT3-ITD at diagnosis in the context of FLT3-ITD MRD.

Mutant NPM1 MRD detection in patients with AML with a concomittant FLT3-ITD. (A) Relapse incidence of mutant NPM1 (mNPM1) MRD (NGS/DNA, >0.01% VAF) in patients with AML without FLT3-ITD at diagnosis. Patients with detectable mNPM1 MRD indicated in yellow, patients without detectable NPM1 MRD indicated in purple. (B) Relapse incidence of mNPM1 MRD (NGS/DNA, >0.01% VAF) in patients with AML with a FLT3-ITD at diagnosis. Patients with detectable mNPM1 MRD indicated in yellow, patients without detectable NPM1 MRD indicated in purple. (C) Relapse incidence of patients with AML with and without mNPM1 MRD in patients with AML with a FLT3-ITD at diagnosis in the context of FLT3-ITD MRD.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal